The retina relies on two distinct sets of cells to see — rods for low light, cones for bright light and colour — and ‘rod-cone dystrophy’ simply names which of the two starts failing first. In this group, it’s the rods, with the cones affected only later, and that sequence is exactly what underlies the vast majority of cases labelled retinitis pigmentosa in clinical practice. It’s a useful distinction because it lets us predict, with reasonable confidence, which visual abilities are likely to fade earliest and which are likely to remain intact the longest.
When a patient from Rwanda arrives with ‘rod-cone dystrophy’ already noted on their referral, spelling out that rod-first sequence at the start of the conversation usually clears up more confusion than any additional test could.
That rod-first pattern comes from mutations in genes that rods depend on more heavily than cones do to stay functional, which explains the substantial genetic overlap with RP more broadly. Depending on which gene is at fault, the condition can be inherited as a dominant trait, a recessive one, or an X-linked one, and it may occur alone or as part of a broader syndrome involving other parts of the body.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
The treatment approach follows the same framework used for the other progressive dystrophies — stem cell therapy is considered for patients whose results support it, combined with practical guidance for managing reduced night and peripheral vision, while central vision continues to work reasonably well for a comparatively long stretch.
There’s substantial overlap between the two terms. ‘Rod-cone dystrophy’ refers to the order in which the disease unfolds — rods first, cones later — and that particular order describes the majority of what gets diagnosed as retinitis pigmentosa.
It comes down to which cell type fails first. In rod-cone dystrophy, night vision and side vision go early while central and colour vision hold up for longer; cone-rod dystrophy runs the other way round, affecting central and colour vision sooner.
For many rod-cone patients, yes, eventually — once the disease has progressed enough to reach the cones. When exactly that happens differs considerably depending on the specific gene and the individual patient involved.
That’s decided case by case, based on how your ERG and field-test results are trending after the first evaluation. Some patients are fine with an annual review, while others whose condition is shifting faster are seen more frequently.
